和黄医药赛沃替尼治疗MET扩增胃癌新药申请在华获受理并纳入优先审评

美股速递
Dec 30, 2025

和黄医药今日宣布,其针对MET扩增胃癌患者的创新药物赛沃替尼的新药申请已获得中国国家药品监督管理局受理,并被纳入优先审评通道。这一进展标志着该药物在中国商业化进程中的重要突破,有望为存在MET基因扩增的胃癌患者提供新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10